Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Denmark |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
21.12.2023 16:25:46 CET | ViroGates | Information about majority shareholder
COMPANY ANNOUNCEMENT - No. 27-2023 – Information about majority shareholder - 21 December 2023
BIRKERØD, DENMARK - ViroGates A/S (“VIRO”), a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that the majority shareholder of the company, N. P. Louis-Hansen ApS, has subscribed for 799,075 shares in the Company as part of the recently completed rights emission, cf. company announcement no. 19-2023 from ViroGates. The shares were allocated on 19th December 2023 and have been transferred to the permanent ISIN as of today.
N. P. Louis-Hansen ApS is the majority shareholder with post-subscription holdings of less than 25% of the share capital and more than 25% of the voting rights in ViroGates A/S.
The announcement can be found at https://www.virogates.com/investor/announcements.
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff as well as to monitor health in the general population.
The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
Disclosure regulation
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
Contacts
- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com